May 13th 2024
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More
Ozanimod Shows Sustained Efficacy in Long-term Study for Multiple Sclerosis Treatment
March 11th 2024Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.
Read More
In a retrospective study, researchers from Humana in Louisville, KY, compared clinical outcomes, time on treatment, healthcare resources utilization, and relative costs in patients with MS that were newly initiated on one of the following oral DMTs: dimethyl fumarate, fingolimod, or teriflunomide.
Read More
Research scientist Dr. Cristina A. F. Román, based at the Kessler Foundation’s Rocco Ortenzio Neuroimaging Center, secured a $704,054 grant for a five-year mixed-method study exploring the impact of healthcare barriers on cardiovascular risk factors and accelerated brain aging in Latinos with multiple sclerosis (MS), an under-researched community facing more severe disease outcomes;
Read More
Real World Study Finds Ocrevus, Helps Highly Disabled People with MS
January 15th 2024Ocrevus (ocrelizumab), marketed by Genentech, is a CD20-directed monoclonal antibody FDA-approved in 2017 to treat relapsing forms of multiple sclerosis (MS) as well as primary progressive MS (PPMS). It's currently the only disease-modifying treatment approved for treating PPMS.
Read More
Study Finds Higher B-Cell Levels in African American Patients with Multiple Sclerosis
November 8th 2023It is believed that reasons for these racial disparities may include socioeconomic factors, but the true causes are not fully understood. Some researchers believe that immunologic differences may also play a role.
Read More
Intranasal Foralumab for Multiple Sclerosis Now Approved by FDA for At-Home Dosing
October 20th 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More
PML, a Rare Side Effect of Tysabri, Found to Worsen Long-Term Disability in Patients with MS
October 11th 2023Progressive multifocal leukoencephalopathy (PML) is caused by John Cunningham virus (JCV). A recently published study suggests that the number of cases of PML related to Tysabri (natalizumab) have been decreasing perhaps as a result of increased monitoring.
Read More
Early Depression Unlikely To Cause More Severe Disability in MS patients, Study Suggests
July 17th 2023Researchers have been working on sorting out the causal direction of multiple sclerosis (MS) and depression. These findings suggest that depression can be a consequences of MS-related disability not the other way around.
Read More